Why J&J Is Poised to Outperform
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health-care products giant Johnson & Johnson has earned a respected four-star ranking.
With that in mind, let's take a closer look at J&J and see what CAPS investors are saying about the stock right now.
J&J facts
Headquarters (founded) | New Brunswick, N.J. (1886) |
Market Cap | $265.1 billion |
Industry | Pharmaceuticals |
Trailing-12-Month Revenue | $70.0 billion |
Management | Chairman/CEO Alex Gorsky |
Return on Equity (average, past 3 years) | 17.9% |
Cash/Debt | $25.1 billion / $15.0 billion |
Dividend Yield | 2.8% |
Competitors | Covidien |
Sources: S&P Capital IQ and Motley Fool CAPS.
Earlier this summer, CAPS member NHWeston102 succinctly summed up the J&J bull case for our community:
JnJ has taken its lumps of late, but it is still a global company with a huge spectrum of well-known brands from baby-powder to band-aids. They are not afraid to buy pioneering companies to catch a leg up on the competition, but JnJ still retains a strong innovative edge of its own. Look, for example, at INVOCANA, a diabetes drug that controls glucose levels through urine stream rather than insulin regulation. A classic buy-and-hold blue chip that still has serious class!!
Dividend stocks can make you rich. It's as simple as that. While they don't garner the notoriety of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.
The article Why J&J Is Poised to Outperform originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool recommends Covidien and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
